Bevacizumab and ocular wound healing after primary pterygium excision

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 1, 2011, Pages 17-21

  Banifatemi, Mohammad ^a   Razeghinejad, M Reza ^a   Hosseini, Hamid ^a   Gholampour, Ahmadreza ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PLACEBO;

ADULT; ARTICLE; CHEMOSIS; CLINICAL ARTICLE; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; CORNEA INJURY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERYTHEMA; EXCISION; FEMALE; HUMAN; LACRIMATION; MALE; PHOTOPHOBIA; POSTOPERATIVE PERIOD; PTERYGIUM; RANDOMIZED CONTROLLED TRIAL; SURGICAL WOUND; WOUND HEALING; WOUND INFECTION;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CONJUNCTIVA; CONJUNCTIVAL DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERYTHEMA; EYE; FEMALE; HUMANS; INJECTIONS, INTRAOCULAR; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; PTERYGIUM; WOUND HEALING;

EID: 79951991353     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0094     Document Type: Article

References (30)

1. Manning, C.A., Kloess, P.M., Diaz, M.D., and Yee, R.W. Intraoperative mitomycin in primary pterygium excision. A prospective, randomized trial. Ophthalmology 104:844-848, 1997.
2. Detorakis, E.T., and Spandidos, D.A. Pathogenetic mechanisms and treatment options for ophthalmic pterygium: trends and perspectives (review). Int. J. Mol. Med. 23:439-447, 2009.
3. Coroneo, M.T., Di Girolamo, N., and Wakefield, D. The pathogenesis of pterygia. Curr. Opin. Ophthalmol. 10:282-288, 1999.
4. Ang, L.P., Chua, J.L., and Tan, D.T. Current concepts and techniques in pterygium treatment. Curr. Opin. Ophthalmol. 18:308-313, 2007.
5. Hirst, L.W. The treatment of pterygium. Surv. Ophthalmol. 48:145-180, 2003.
6. Razeghinejad, M.R., Hosseini, H., Ahmadi, F., Rahat, F., and Eghbal, H. Preliminary results of subconjunctival bevacizumab in primary pterygium excision. Ophthalmic Res. 43:134-138, 2010.
7. Mauro, J., and Foster, C.S. Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment. Semin. Ophthalmol. 24:130-134, 2009.
8. Costagliola, C., Cipollone, U., Rinaldi, M., della Corte, M., Semeraro, F., and Romano, M.R. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. Br. J. Clin. Pharmacol. 66:667-673, 2008.
9. Lalwani, G.A., Berrocal, A.M., Murray, T.G., Buch, M., Cardone, S., Hess, D., Johnson, R.A., and Puliafito, C.A. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 28:S13-S18, 2008. (Pubitemid 351644418)
10. Brouzas, D., Charakidas, A., Moschos, M., Koutsandrea, C., Apostolopoulos, M., and Baltatzis, S. Bevacizumab (Avastin) for the management of anterior chamber neovascularization and neovascular glaucoma. Clin. Ophthalmol. 3:685-688, 2009.
11. Fong, D.S., Custis, P., Howes, J., and Hsu, J.W. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: a multicenter, retrospective study. Ophthalmology 117:298-302, 2010.
12. Kim, S.W., Ha, B.J., Kim, E.K., Tchah, H., and Kim, T.I. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 115:e33-e38, 2008.
13. Andriolo, R.B., Puga, M.E., Belfort Junior, R., and Atallah, A.N. Bevacizumab for ocular neovascular diseases: a systematic review. Sao Paulo Med. J. 127:84-91, 2009.
14. Kamba, T., and McDonald, D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 96:1788-1795, 2007. (Pubitemid 46912024)
15. August, D.A., Serrano, D., and Poplin, E. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J. Surg. Oncol. 97:180-185, 2008.
16. Wu, Y., Zhang, Q., Ann, D.K., Akhondzadeh, A., Duong, H.S., Messadi, D.V., and Le, A.D. Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts. Am. J. Physiol. Cell Physiol. 286:C905-C912, 2004.
17. Brown, L.F., Yeo, K.T., Berse, B., Yeo, T.K., Senger, D.R., Dvorak, H.F., and van de Water, L. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J. Exp. Med. 176:1375-1379, 1992.
18. DeStafeno, J.J., and Kim, T. Topical bevacizumab therapy for corneal neovascularization. Arch. Ophthalmol. 125:834-836, 2007.
19. Bock, F., Onderka, J., Rummelt, C., Dietrich, T., Bachmann, B., Kruse, F.E., Schlotzer-Schrehardt, U., and Cursiefen, C. Safety profile of topical VEGF neutralization at the cornea. Invest. Ophthalmol. Vis. Sci. 50:2095-2102, 2009.
20. Carrasco, M.A. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea 27:743-745, 2008.
21. Kim, T.I., Chung, J.L., Hong, J.P., Min, K., Seo, K.Y., and Kim, E.K. Bevacizumab application delays epithelial healing in rabbit cornea. Invest. Ophthalmol. Vis. Sci. 50:4653-4659, 2009.
22. Ho, Q.T., and Kuo, C.J. Vascular endothelial growth factor: biology and therapeutic applications. Int. J. Biochem. Cell Biol. 39:1349-1357, 2007.
23. Ben-Av, P., Crofford, L.J., Wilder, R.L., and Hla, T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 372:83-87, 1995.
24. Zakarija, A., and Soff, G. Update on angiogenesis inhibitors. Curr. Opin. Oncol. 17:578-583, 2005.
25. Seipelt, R.G., Backer, C.L., Mavroudis, C., Stellmach, V., Seipelt, I.M., Cornwell, M., Hernandez, J., and Crawford, S.E. Topical VEGF enhances healing of thoracic aortic anastomosis for coarctation in a rabbit model. Circulation 108 Suppl 1:II150-II154, 2003.
26. D'Angelica, M., Kornprat, P., Gonen, M., Chung, K.Y., Jarnagin, W.R., DeMatteo, R.P., Fong, Y., Kemeny, N., Blumgart, L.H., and Saltz, L.B. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann. Surg. Oncol. 14:759-765, 2007.
27. Lee, S.H., Leem, H.S., Jeong, S.M., and Lee, K. Bevacizumab accelerates corneal wound healing by inhibiting TGF-beta2 expression in alkali-burned mouse cornea. BMB Rep. 42:800-805, 2009.
28. Furrer, P., Mayer, J.M., and Gurny, R. Ocular tolerance of preservatives and alternatives. Eur. J. Pharm. Biopharm. 53:263-280, 2002.
29. Collin, H.B. Ultrastructural changes to corneal stromal cells due to ophthalmic preservatives. Acta Ophthalmol. (Copenh). 64:72-78, 1986.
30. Collin, H.B., and Grabsch, B.E. The effect of ophthalmic preservatives on the healing rate of the rabbit corneal epithelium after keratectomy.Am. J. Optom. Physiol. Opt. 59:215-222, 1982.